&nbsp;

FactsAboutSmokingCOVID-19CancerTreatment.pdf

Jan 2021

Document

FactsAboutSmokingCOVID-19CancerTreatment-FR.pdf

Jan 2021

Regimen

NIVL+IPIL(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

FEDR

Cancer Type:

Hematologic,

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

Exceptional Access Program

fedratinib - For the treatment of splenomegaly and/or disease related symptoms of myelofibrosis according to clinical criteria

Drugs Used:

fedratinib

Quick Link(s):

Regimen Monograph

Jan 2025

First Nations, Inuit, Métis and Urban Indigenous Cancer Screening Resources

Document

fn-brochure-thumbnail.jpg

Apr 2021

Document

fn-fr-brochure-thumbnail.jpg

May 2021

Document

NursingPracticeContinuum.pdf

Jun 2021

Document

FrequentlyAskedQuestions-OCRSEERStat12a.pdf

Jun 2021

Drug

niraparib

Other Name(s): Zejula

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2025

Regimen

NIVL+IPIL

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)